• Mashup Score: 0

    July 27, 2023 —UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced that it has been granted FDA clearance for its AI-powered ultrasound guidance technology. The UltraSight real-time AI guidance software can assist medical professionals without sonography experience in acquiring cardiac ultrasound images at the point of care in multiple settings, allowing for more widespread detection of heart disease and providing patients easier access to cardiac monitoring.  With more than 8 million patients admitted to U.S. emergency departments every year with symptoms concerning for heart attack or heart failure according to the Centers for Disease Control and Prevention, access to timely and accurate cardiac ultrasound in the acute care setting can save lives. In addition, approximately 30 million heart disease patients in the U.S. continue to require periodic cardiac monitoring. However, significant bottlenecks within the U.S.

    Tweet Tweets with this article
    • @DAICeditor @UltraSightAI New #AI guidance software will allow more #medical professionals to conduct #cardiac #ultrasound in multiple care settings expanding patient access to #cardiacimaging: https://t.co/T6k5ZqSHhP

  • Mashup Score: 2
    Wolters Kluwer Health - 10 month(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Tweet Tweets with this article
    • A first-in-human clinical trial demonstrated that low-intensity pulsed #ultrasound with concomitant administration of intravenous microbubbles opens the blood-brain barrier, which allows for safe, repeated penetration of #cytotoxicdrugs into the brain. https://t.co/bIimFL8jNV https://t.co/3wReO8vKf8

  • Mashup Score: 0

    Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than Intravascular ultrasound (IVUS), making it ideal for clinical trials of cardiovascular (and other) drug candidates. Additionally, advances in computing and artificial intelligence (AI) are enabling precise measurement of changes in atherosclerosis disease progression, including…

    Tweet Tweets with this article
    • @DAICeditor @itnEditor @dgsomucla @BudoffMd @the_lundquist #Coronary #computedtomography #angiography is a cheaper, less-invasive alternative to #intravascular #ultrasound in #pharmaceutical clinical trials: https://t.co/vPYf0SuomV